1 / 38

Jeffrey A. Bogart M.D. Upstate Medical University November 15, 2013

Proton Therapy for Lung Cancer Therapeutic Advance or The Straw that Broke the U.S. Medical System’s Back?. Jeffrey A. Bogart M.D. Upstate Medical University November 15, 2013. Disclosures. Chair, Alliance Radiation Oncology Committee Stipend

fisseha
Télécharger la présentation

Jeffrey A. Bogart M.D. Upstate Medical University November 15, 2013

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Proton Therapy for Lung CancerTherapeutic AdvanceorThe Straw that Broke the U.S. Medical System’s Back? Jeffrey A. Bogart M.D. Upstate Medical University November 15, 2013

  2. Disclosures • Chair, Alliance Radiation Oncology Committee • Stipend • Upstate Medical University recently signed a MOU with Advanced Oncotherapy PLC to proceed with developing a proton therapy center

  3. Learning Objectives • Review current state of the art (radio)therapy for locally advanced NSCLC • Describe available evidence for proton therapy in treatment of early stage NSCLC • Discuss opportunities and challenges in treatment of locally advanced NSCLC with proton therapy

  4. Background • Stage III NSCLC • Primary RT: Local tumor control ~ 15% • ChemoRT: In-field failure 33%+ (RTOG 9410) • Hypothesis: Modulating RT delivery will improve local control and ultimately survival

  5. RT Practice Standards • The new millennium … • IMRT, IGRT, 4D planning now routine • Should shift therapeutic index • But ..no change in the radiotherapy dose schedule for locally advanced NSCLC since the 1970’s • 6000 cGy / 6 weeks

  6. 3D Dose Escalation • Dose Escalation : Conventional Fractionation • 74 Gy in 2 Gy fractions was feasible with concurrent weekly paclitaxel and carboplatin

  7. Concurrent Chemotherapy: RTOG 0617 Bradley, ASCO 2013

  8. RTOG 0617 Local Relapse also increased (37%) on 74 Gy arm Well conducted trial allowing state of the art technology and good QA Bradley, ASCO 2013

  9. Conventional RT Traditional “protracted” dose escalation is a flawed and failed strategy in combined modality therapy Locally Advanced NSCLC Protracted Conventional Radiotherapy

  10. What Now? • Alternate Radiotherapy Schedules

  11. Hyperfractionation • RTOG 9410: 1.2 Gy BID to 69.6 Gy • Lower dose per fx reduced toxicity? Curran, JNCI 2011

  12. Higher dose per fraction Safe with advanced technology? Hypofractionation

  13. Active Photon Studies Stage III ChemoRT • CALGB 31102 • Phase I : Maintain Total Dose at 60Gy • Increase dose/fraction - reduce treatment time • Next cohort : 3 Gy x 20 Fx over 4 weeks RTOG 1106 • Random phase II : individualized adaptive RT using during-treatment FDG-PET/CT • Doses as high as 85 Gy in 30 fx given

  14. What Else? • Charged particle therapy

  15. Proton Therapy • + Charged Particle • Physical properties differ from photons • Potential for better protection of normal structures • But treatment planning relatively immature c/w photons • Passive Scattering (~ 3D) : majority of published studies • IMPT (~ IMRT) – dose painting • Biologic efficacy similar

  16. Precise Energy Placement

  17. Pediatric Malignancies • Reduced dose to normal tissue • limit impact on growth • reduce secondary malignancy risk

  18. Proton Therapy Cost : $25,000,000 to > $200,000,000

  19. Building Boom of Proton Beam Centers Flares Up in Washington and Baltimore Cancer Letter : Oct 25, 2013 “About 100,000 people have been treated with proton beam radiation, and about 85 percent of them received it for prostate cancer “ • - Level 1 evidence supporting protons over photons does not exist • Undue severe toxicity has not been reported

  20. Early Lung Cancer

  21. Photon SBRT

  22. “Protons generate larger high-dose regions than photons because of range uncertainties. This can result in nearby healthy organs (e.g., chest wall) receiving close to the prescription dose, at least when two to three beams are used, such as in our study” Seco et al Red Journal 2012

  23. Reduced (low dose) lung , heart , esophagus dose with proton SBRT Georg Radioth Onc 2008

  24. Photon SBRT RTOG 0236 60 Gy / 3 fx (peripheral tumors only) 97% in-field local control Timmerman JAMA 2010

  25. Proton Therapy Early Lung Cancer • Loma Linda (2013) • 111 patients, T1+ T2 tumors • 4-year OS dose dependent :18% (50 Gy), 32% (60 Gy), 51%(70 Gy) • Local Control 96% for Peripheral T1 if 60 Gy + • Clinical radiation pneumonitis was not found to be a significant complication • “Meta-analysis” (2010) • “Five-year overall survival similar with SBRT (42%), proton therapy (40%) and carbon-iontherapy (42%). However, caution is warranted due to the limited number of patients and limited length of follow-up of the particle studies” Bush et al Red Journal 2013 Grutters et al RadiothOncol 2010

  26. Proton Therapy Locally Advanced Lung Cancer Photon IMRT

  27. Proton Therapy Locally Advanced Lung Cancer V20 Lung = Volume of Lung Receiving 20 Gy

  28. Proton Therapy Locally Advanced NSCLC Chang et al Red Journal 2006

  29. Stage III NSCLC • Does what we see on paper (or the computer screen) translate into real life?

  30. Proton Therapy Locally Advanced Lung Cancer Complicating Factors Depth of penetration /Bragg peak varies significantly based on the density of tissues Range uncertainty (extra margin of safety) Tumor Motion introduces further uncertainty

  31. PT + ChemotherapyStage III NSCLC Phase II (MD Anderson, n = 44) • 74 Gy(RBE)+ weekly carboplatin (AUC 2) and paclitaxel (50 mg/m2 ) • FDG-PET/CT staged • passively scattered proton • Cone beam CT not available • Median Survival 29.4 months (19.7 month median FU) • Local relapse 20.5 % , 9.3 % nodal relapse • Toxicity • 11.4% grade 3 dermatitis , 11.4% grade 3 esophagitis • 1 grade 3 pneumonitis and 1 pulmonary/pleural fistula Chang et al Cancer 2011

  32. PT + ChemotherapyStage III NSCLC University of Florida (n = 19) • Median 74 Gy(RBE) + chemotherapy • Median 16 month FU • Toxicity • 1 acute grade 3 and 1 late grade 3 non-hematologic toxicity • 1 documented in-field progression Hoppe et al Lung Cancer 2012

  33. Locally Advanced • Primary RT • Poor DFS/OS with PT alone • Re-irradiation(n= 33) • MD Anderson • Repeat RT to 66 Gy (median 3 year interval) • 54% 1-yr local control, 9/33 in-field relapse • Toxicity • Gr 3 : 9% Esophageal, 21 % pulmonary • Gr 4 : 3% Esophageal, 7 % pulmonary • PORT/Mediastinal RT • Better Protect Heart and Surrounding Lung c/w photon McAvoy et al RadiotherOncol 2013

  34. RTOG 1308: Phase III Randomized Trial Comparing Overall Survival after Photon vs. Proton Radiochemotherapy for Stage II-IIIB NSCLC • Stratify • Stage • 1.II • 2.IIIA • 3.IIIB • GTV • 1.<= 130 cc • 2.>130 cc • Histology • 1.Squamous • 2.Non-Squamous • Neoadjuvant • Chemotherapy • Yes • No RANDOMIZATION Arm 1 Photon: Highest achievable dose between 60-70 Gy at 2 Gy, once daily plus platinum-based doublet chemotherapy Arms 1 and 2: Consolidation Chemotherapy x 2 is allowed Arm 2 Protons: Highest achievable dose between 60-70 Gy (RBE) at 2 Gy (RBE) once daily plus platinum-based doublet chemotherapy Plan must meet dose and volume constraints of all OARs

  35. Stage III Trials • Ongoing and planned trials evaluating proton therapy • Preoperative therapy • Hypofractionated • IMPT with simultaneous integrated boost

  36. Conclusions • RTOG 0617 set the bar high : 28 month median OS • Modern staging (FDG-PET) • Sophisticated Treatment Planning • Whether altering fractionation, dose , or treatment particle will improve outcomes is unclear • Proton therapy has potential to permit less toxic delivery of intensive RT … but limited data • Treatment techniques rapidly evolving (IMPT/CBCT) • PT may facilitate getting to the the right RT schedule

More Related